Canaccord Genuity Thinks Metacrine’s Stock is Going to Recover


In a report released yesterday, Edward Nash from Canaccord Genuity maintained a Buy rating on Metacrine (MTCR), with a price target of $19.00. The company’s shares closed last Tuesday at $8.39, close to its 52-week low of $7.64.

According to TipRanks.com, Nash is a 3-star analyst with an average return of 4.7% and a 40.8% success rate. Nash covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Galmed Pharmaceuticals, and Akero Therapeutics.

Currently, the analyst consensus on Metacrine is a Strong Buy with an average price target of $20.67.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts